Vincera
Vincera is engaged in the development of new therapies to address unmet medical needs for the treatment of cancer.
This post is for subscribers only
SubscribeAlready have an account? Log in
DocGo $DCGO Paid Members Public
DocGo $DCGO has earned another look after the recent share decline. Our estimates suggest a good deal of upside and an undervalued situation. This post goes through our initial case and cut at the numbers for Q4 and 2023.
